FDA Accepts Application for Investigational Nerve Visualization Drug Bevonescein

The FDA has accepted Alume Biosciences' New Drug Application (NDA) for bevonescein, an investigational fluorescent drug. This drug is designed to enhance nerve visualization during head and neck surgery, potentially improving patient safety and surgical outcomes by providing clear contrast between nerves and surrounding tissue.